Schizophrenia Research
Volume 120, Issue 1 , Pages 191-198 , July 2010

Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia

  • Nicoletta M.J. van Veelen

      Affiliations

    • Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author. Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, Room A.00.241, P.O. Box 85500, NL-3508 GA Utrecht, The Netherlands. Tel.: +31 88 7558180; fax: +31 88 7555443.
    • ,
  • Koen. P. Grootens

      Affiliations

    • Radboud University Medical Center, Nijmegen, The Netherlands
    • Currently at CWZ Hospital Nijmegen, The Netherlands.
    • ,
  • J. Peuskens

      Affiliations

    • University Psychiatric Center, Catholic University of Leuven, campus Kortenberg, Belgium
    • ,
  • B.G.C. Sabbe

      Affiliations

    • Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Belgium
    • ,
  • Miriam E. Salden

      Affiliations

    • Center of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University, Tilburg, The Netherlands
    • ,
  • R.J. Verkes

      Affiliations

    • Radboud University Medical Center, Nijmegen, The Netherlands
    • ,
  • René S. Kahn

      Affiliations

    • Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Margriet M. Sitskoorn

      Affiliations

    • Center of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University, Tilburg, The Netherlands

Received 21 October 2009 ,Revised 19 April 2010 ,Accepted 26 April 2010.

References 

  1. Albus M, Hubmann W, Scherer J, Dreikorn B, Hecht S, Sobizack N, et al. A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2002;252:262–267
  2. Albus M, Hubmann W, Mohr F, Hecht S, Hinterberger-Weber P, Seitz NN, et al. Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. Eur. Arch. Psychiatry Clin. Neurosci. 2006;256:442–451
  3. Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry. 1999;156:1358–1366
  4. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City: University of Iowa; 1976;Ref Type: Generic
  5. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry. 2000;157:549–559
  6. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 2002;159:1018–1028
  7. Blyler CR, Gold JM, Iannone VN, Buchanan RW. Short form of the WAIS-III for use with patients with schizophrenia. Schizophr. Res. 2000;46:209–215
  8. Brazo P, Marie RM, Halbecq I, Benali K, Segard L, Delamillieure P, et al. Cognitive patterns in subtypes of schizophrenia. Eur. Psychiatry. 2002;17:155–162
  9. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988;26:223–238
  10. Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M, et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J. Clin. Psychiatry. 2009;70:717–729
  11. Cuesta MJ, Jalon EG, Campos MS, Peralta V. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br. J. Psychiatry. 2009;194:439–445
  12. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry. 2009;166:675–682
  13. Dominguez MG, Viechtbauer W, Simons CJ, van OJ, Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol. Bull. 2009;135:157–171
  14. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 1976;33:766–771
  15. Erlenmeyer-Kimling L, Rock D, Roberts SA, Janal M, Kestenbaum C, Cornblatt B, et al. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am. J. Psychiatry. 2000;157:1416–1422
  16. First M, Spitzer R, Gibbon M, Williams JBW. Interview for DSM-IV Axis I Disorders — Patient Edition (SCID-I/P, version 2.0). 1996;Ref Type: Generic
  17. Freedman LR, Rock D, Roberts SA, Cornblatt BA, Erlenmeyer-Kimling L. The New York High-Risk Project: attention, anhedonia and social outcome. Schizophr. Res. 1998;30:1–9
  18. Friis S, Sundet K, Rund BR, Vaglum P, McGlashan TH. Neurocognitive dimensions characterising patients with first-episode psychosis. Br. J. Psychiatry Suppl. 2002;43:s85–s90
  19. Gibel A, Ritsner MS. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Clin. Neuropharmacol. 2008;31:204–220
  20. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry. 2007;64:1115–1122
  21. Gonzalez-Blanch C, Crespo-Facorro B, varez-Jimenez M, Rodriguez-Sanchez JM, Pelayo-Teran JM, Perez-Iglesias R, et al. Pretreatment predictors of cognitive deficits in early psychosis. Psychol. Med. 2008;38:737–746
  22. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153:321–330
  23. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr. Bull. 2000;26:119–136
  24. Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr. Bull. 2009;
  25. Gurpegui M, Alvarez E, Bousono M, Ciudad A, Carlos GJ, Olivares JM. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. Eur. Neuropsychopharmacol. 2007;17:725–734
  26. Hammes JGW. De Stroop Kleur Woord Test. Manual. 1971;Lisse, Swets&Zeitlinger. Ref Type: Generic
  27. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am. J. Psychiatry. 1998;155:1080–1086
  28. Harvey PD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl). 2004;172:324–332
  29. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am. J. Psychiatry. 2005;162:1888–1895
  30. Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J. Neuropsychiatry Clin. Neurosci. 2006;18:54–63
  31. Heaton RK, Chelune GJ Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test Manual — revised and expanded. USA: PARPsychological Assessment Resources, inc; 1993;Ref Type: Generic
  32. Heinrichs RW. The primacy of cognition in schizophrenia. Am. Psychol. 2005;60:229–242
  33. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–445
  34. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984;10:388–398
  35. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr. Res. 2004;68:1–9
  36. Hill SK, Beers SR, Kmiec JA, Keshavan MS, Sweeney JA. Impairment of verbal memory and learning in antipsychotic-naive patients with first-episode schizophrenia. Schizophr. Res. 2004;68:127–136
  37. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am. J. Psychiatry. 1999;156:1336–1341
  38. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  39. Keefe RS. Cognitive deficits in patients with schizophrenia: effects and treatment. J. Clin. Psychiatry. 2007;68(Suppl 14):8–13
  40. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry. 2004;161:985–995
  41. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31:2033–2046
  42. Keefe RS, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr. Res. 2006;88:26–35
  43. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol. Psychiatry. 2006;59:97–105
  44. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry. 2007;64:633–647
  45. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry. 2007;164:1061–1071
  46. Kopelowicz A, Liberman RP, Ventura J, Zarate R, Mintz J. Neurocognitive correlates of recovery from schizophrenia. Psychol. Med. 2005;35:1165–1173
  47. Kraus MS, Keefe RS. Cognition as an outcome measure in schizophrenia. Br. J. Psychiatry Suppl. 2007;50:s46–s51
  48. Leeson VC, Robbins TW, Franklin C, Harrison M, Harrison I, Ron MA, et al. Dissociation of long-term verbal memory and fronto-executive impairment in first-episode psychosis. Psychol. Med. 2009;1–10
  49. Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, et al. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol. Psychiatry. 2006;59:863–871
  50. Lewis R. Should cognitive deficit be a diagnostic criterion for schizophrenia?. J. Psychiatry Neurosci. 2004;29:102–113
  51. Luborsky L. Clinicians' judgements of mental health. Arch. Gen. Psychiatry. 1962;7:407–417Ref Type: Generic
  52. Luteyn F, Van der Ploeg FAE. The Groningen Intelligence Test (in Dutch). Lisse, the Netherlands: Swets and Zeitlinger; 1983;Ref Type: Generic
  53. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch. Gen. Psychiatry. 1999;56:749–754
  54. Mulder JL, Dekker R, Dekker PH. Verbale Leer en Geheugen Test. Lisse, the Netherlands: Swets and Zeitlinger; 1996;Ref Type: Generic
  55. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004;72:29–39
  56. Oie M, Rund BR. Neuropsychological deficits in adolescent-onset schizophrenia compared with attention deficit hyperactivity disorder. Am. J. Psychiatry. 1999;156:1216–1222
  57. Palmer BW, Heaton RK, Paulsen JS, Kuck J, Braff D, Harris MJ, et al. Is it possible to be schizophrenic yet neuropsychologically normal?. Neuropsychology. 1997;11:437–446
  58. Paulsen JS, Heaton RK, Sadek JR, Perry W, Delis DC, Braff D, et al. The nature of learning and memory impairments in schizophrenia. J. Int. Neuropsychol. Soc. 1995;1:88–99
  59. Reitan RM. Trail Making Test. manual for administration and scoring. 2920 South 4th Avenue, Tuscon, Ariona: Reitan Neuropsychology Laboratory; 1992;Ref Type: Generic
  60. Rodriguez-Sanchez JM, Perez-Iglesias R, Gonzalez-Blanch C, Pelayo-Teran JM, Mata I, Martinez O, et al. 1-year follow-up study of cognitive function in first-episode non-affective psychosis. Schizophr. Res. 2008;104:165–174
  61. Rund BR, Melle I, Friis S, Larsen TK, Midboe LJ, Opjordsmoen S, et al. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am. J. Psychiatry. 2004;161:466–472
  62. Rund BR, Melle I, Friis S, Johannessen JO, Larsen TK, Midboe LJ, et al. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr. Res. 2007;91:132–140
  63. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry. 1994;51:124–131
  64. Sharma T, Hughes C, Soni W, Kumari V. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology (Berl). 2003;169:398–403
  65. Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A double-blind cross-over study. Br. J. Psychiatry. 1995;166:241–243
  66. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?. J. Nerv. Ment. Dis. 2000;188:518–524
  67. Wechsler D. Wechsler Memory Scale — Revised: Verbal Paired Associates. The Psychological Corporation Harcourt Brace Jovanovich, Inc; 1987;Ref Type: Generic
  68. Wechsler D. Wechsler Memory Scale —Revised, visual reproduction. 1987. San Antonio, San Diego, Orlando, New York, chicago, Toronto, The psychological corporation Harcourt Brace Jovanovich, inc.Ref Type: Generic.
  69. Wechsler D. WAIS-III: Wechsler Adult Intelligence Scale. Administration and Scoring Manual. 3rd ed. San Antonio: Psychological Corporation/Harcourt Brace; 1997;Ref Type: Generic
  70. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005;8:457–472
  71. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr. Res. 2007;89:211–224
  72. Zakzanis . Neuropsychological Differential Diagnosis. Lisse, the Netherlands: Swets and Zeitlinger; 1999;Ref Type: Generic

PII: S0920-9964(10)01264-8

doi: 10.1016/j.schres.2010.04.011

Schizophrenia Research
Volume 120, Issue 1 , Pages 191-198 , July 2010

Article Tools